Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 Oct 2008

Grossman Iris, Sullivan Patrick F, Walley Nicole, Liu Youfang, Dawson Jeffrey R, Gumbs Curtis, Gaedigk Andrea, Leeder J Steven, McEvoy Joseph P, Weale Michael E, Goldstein David B

Abstract excerpt

PURPOSE: To evaluate systematically in real clinical settings whether functional genetic variations in drug metabolizing enzymes influence optimized doses, efficacy, and safety of antipsychotic medications. METHODS: DNA was collected from 750 patients with chronic schizophrenia treated with five antipsychotic drugs (olanzapine, quetiapine, risperidone, ziprasidone, and perphenazine) as part of the Clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Genetic Variation

Share to Schizophrenia

Source

Open in PubMed Open full text

Identifiers

PMID: 18813134
DOI: 10.1097/GIM.0b013e3181863239
PMCID: PMC3697113

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.PMID 18813134Read ↗

Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic TreatmentsSemantic proximity Read ↗

Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia.Semantic proximity Read ↗

Use of candidate gene markers to guide antipsychotic dosage adjustment.Semantic proximity Read ↗

Pharmacogenetics of AntipsychoticsSemantic proximity Read ↗

Pharmacogenetics of antipsychotics: Clinical utility and implementationSemantic proximity Read ↗

Pharmacogenetics-Guided Advances in Antipsychotic Treatment.Semantic proximity Read ↗

Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine MetabolismSemantic proximity Read ↗

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Semantic proximity Read ↗

GENETIC VARIANTS IN ANTIPSYCHOTIC METABOLISM: POLYMORPHISM PROFILES IN KAZAKH COHORT WITH PARANOID SCHIZOPHRENIA.Semantic proximity Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

Interindividual Variability in Olanzapine Steady-State Concentrations in Chinese: Exploring Single Nucleotide Polymorphisms of Metabolic EnzymesSemantic proximity Read ↗

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.